Charlie Maynard

I thank my hon. Friend the Member for Wokingham (Clive Jones) for securing this fantastic debate. I also thank the Members in the room for all the work they have done, and the Minister for her engagement, particularly with the Brain Cancer Justice team. I really appreciate it. My sister Georgie received a glioblastoma multiforme diagnosis two and a half years ago. She is well, has survived longer than they gave her and is fighting like hell for Brain Cancer Justice, alongside many in this room. I praise her and her colleagues, as well as so many people in my constituency in Witney who have helped her and who suffer with this range of cancers. I will say only two things today. First, we should explore reforming the Human Tissue Act 2004 to apply to tumour tissue a default system similar to the one we now use nationally for organ donation. To do so, Parliament would need to amend the Act to introduce a deemed consent regime for residual tumour tissue and derived data, limited to public interest cancer research, with a statutory opt-out, strict purpose limits and enhanced oversight by the Human Tissue Authority. The model would mirror the Organ Donation (Deemed Consent) Act 2019, which means that if someone dies their organs are automatically taken, although people or their families can opt out. We are advocating the same for our tumour tissue. Very few of us really want to hang on to our tumour tissue if we are unfortunate enough to be in that situation, but that tumour tissue has huge scientific value and we should use the data as much as we can for the public good. Denmark is a fantastic model: it has a registry-first legal architecture with mandatory health registries covering cancer diagnosis, pathology, genomics, treatment and outcomes. Secondly, we need to double the survival rates for all less survivable cancers in the next decade. If we put that mark in the sand as our goal, and it gets into the national cancer plan, it will draw global attention and will drag resources and talent to our cause and our country. It would be good for our country, good for our patients who are suffering, and good for our economy too. If we can make that a key demand of our national cancer plan, that will be a huge plus.